Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PIRMELLA 7/7/7 vs NORTREL 0.5/35-21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
Combination hormonal contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone inhibits ovulation by suppressing gonadotropin release (LH and FSH) and alters cervical mucus and endometrial receptivity. Ethinyl estradiol provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing ovulation.
Treatment of chronic hepatitis C virus (HCV) genotype 1 infection in combination with other antiviral agents
Prevention of pregnancy,Acne vulgaris (FDA-approved for moderate acne in women ≥15 years who have achieved menarche and desire contraception)
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
1 tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 0.5 mg norethindrone and 35 mcg ethinyl estradiol.
Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days.
Norethindrone: terminal half-life approximately 7-8 hours. Ethinyl estradiol: terminal half-life approximately 13-27 hours, mean about 17 hours. Ethinyl estradiol exhibits a longer half-life due to enterohepatic recirculation and extensive tissue distribution.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min), use is not recommended due to potential fluid retention and hormonal accumulation.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (GFR < 30 m L/min) due to potential for fluid retention and hyperkalemia.
None
PIRMELLA 7/7/7 is a combined hormonal contraceptive containing ethinylestradiol and drospirenone. First trimester: Epidemiologic studies have not found an increased risk of major birth defects; however, inadvertent use in early pregnancy is not associated with teratogenicity. Second and third trimesters: Not indicated for use; animal studies show no teratogenic effects, but data in humans are insufficient. Overall, the FDA assigns a Pregnancy Category X due to the lack of need during pregnancy and potential fetal harm from hormonal exposure (e.g., masculinization of female fetuses with progestins).
FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester: Increased risk of congenital anomalies, including cardiac defects and limb reduction defects (odds ratio 1.5-2.0). Second and third trimesters: Risk of feminization of male fetus, hepatic adenoma, and other adverse effects. Exposure during pregnancy may increase risk of neurodevelopmental disorders.
PIRMELLA 7/7/7 is a prenatal vitamin formulation containing 7 key vitamins and minerals each at 7 mg or mcg doses. Notably, it includes iron (7 mg) and folic acid (7 mcg). The low iron dose may be insufficient for patients with anemia; consider additional supplementation. Folic acid at 7 mcg is below standard prenatal recommendation (400-800 mcg); ensure patient is on an additional folic acid supplement. The '7/7/7' suggests equal dosing of three components—likely folic acid, iron, and calcium—but verify actual constituents. Do not exceed recommended daily intake; some multivitamins contain toxic doses of fat-soluble vitamins.
NORTREL 0.5/35-21 is a combination oral contraceptive containing norethindrone 0.5 mg and ethinyl estradiol 35 mcg. It is a monophasic pill with 21 active tablets followed by 7 placebo tablets. Clinicians should note that the low-dose norethindrone may be less effective in preventing ovulation in some women, increasing the risk of breakthrough bleeding. This formulation is often used for cycle regulation and mild acne. Assess for contraindications including thrombotic disorders, migraine with aura, and smoking in women over 35.
No interactions on record
No interactions on record
Common clinical questions about PIRMELLA 7/7/7 vs NORTREL 0.5/35-21, answered by our medical review team.
PIRMELLA 7/7/7 is a Oral Contraceptive that works by Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.. NORTREL 0.5/35-21 is a Oral Contraceptive that works by Combination hormonal contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone inhibits ovulation by suppressing gonadotropin release (LH and FSH) and alters cervical mucus and endometrial receptivity. Ethinyl estradiol provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing ovulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PIRMELLA 7/7/7 and NORTREL 0.5/35-21 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PIRMELLA 7/7/7 is: PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.. The standard adult dose of NORTREL 0.5/35-21 is: 1 tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 0.5 mg norethindrone and 35 mcg ethinyl estradiol.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PIRMELLA 7/7/7 and NORTREL 0.5/35-21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PIRMELLA 7/7/7 is classified as Category C. PIRMELLA 7/7/7 is a combined hormonal contraceptive containing ethinylestradiol and drospirenone. First trimester: Epidemiologic studies have not found an increased risk of major b. NORTREL 0.5/35-21 is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester: Increased risk of congenital anomalies, including cardiac defects and limb reduction defects (odds ratio 1.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Primarily metabolized by CYP3A4; also undergoes glucuronidation via UGT1A1. It is a substrate of P-glycoprotein.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement; ethinyl estradiol: hepatic via CYP3A4, undergoes sulfation and glucuronidation. Both are excreted in urine and feces.
Renal: 70% unchanged; fecal: 30% as metabolites.
Norethindrone is primarily excreted renally (approximately 60-80% as metabolites) and approximately 20-40% fecally. Ethinyl estradiol is excreted renally (about 40%) and fecally (about 60%) as glucuronide and sulfate conjugates.
95% bound to albumin and alpha-1-acid glycoprotein.
Norethindrone: 60-70% bound to albumin and SHBG. Ethinyl estradiol: 95-98% bound to albumin and 2-5% free; increases SHBG levels, which further affects norethindrone binding.
1.2 L/kg. Indicates extensive tissue distribution.
Norethindrone: Vd approximately 4 L/kg (400 L/70kg), indicating extensive tissue distribution. Ethinyl estradiol: Vd approximately 2.5-4 L/kg (175-280 L/70kg), also widely distributed.
Oral: 45% (first-pass metabolism). Intravenous: 100%.
Norethindrone: oral bioavailability approximately 50-70% due to first-pass metabolism. Ethinyl estradiol: oral bioavailability approximately 40-50% due to first-pass metabolism.
Contraindicated in patients with Child-Pugh class B or C cirrhosis. For Child-Pugh class A, use with caution and monitor liver function; no specific dose adjustment is established.
Contraindicated in acute hepatic disease, hepatic adenomas, or severe cirrhosis (Child-Pugh C). Use with caution in Child-Pugh A or B; dose adjustment not specifically defined, but monitor liver function.
Not indicated for use before menarche. For postmenarchal adolescents, dosing is the same as adults: one tablet daily for 28 days.
Not indicated for use before menarche. For post-menarchal adolescents, same dosing as adults: 1 tablet orally once daily for 21 days, then 7 days off.
Not indicated for use in postmenopausal women. No geriatric-specific dosing; contraindicated in women over 35 who smoke or have cardiovascular risk factors.
Not indicated for use in postmenopausal women due to increased risk of cardiovascular events and venous thromboembolism. No specific dose adjustment in elderly; avoid use in women over 35 who smoke.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. Women who use combination hormonal contraceptives should be strongly advised not to smoke, especially women over 35 years of age and those who smoke 15 or more cigarettes per day.
Calcium-rich foods (e.g., dairy, fortified juices) and antacids can inhibit iron absorption. Caffeine (coffee, tea) and tannins (tea) reduce iron absorption. Vitamin C enhances iron absorption; taking with orange juice may be beneficial. Avoid taking with high-fiber foods or whole grains immediately as they can bind minerals.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels; avoid excessive intake. St. John's Wort and certain herbal supplements can reduce contraceptive efficacy. High-fat meals may slightly delay absorption but not significantly affect overall efficacy.
Combined hormonal contraceptives may reduce milk production and breast milk composition. The ethinylestradiol and drospirenone components are excreted in human milk in small amounts. The milk-to-plasma (M/P) ratio for ethinylestradiol is approximately 0.004 and for drospirenone is not well-established but likely low. Use during lactation is generally not recommended, especially in the first 6 weeks postpartum, due to potential effects on infant estrogen receptors. Alternative methods are preferred.
Excreted in breast milk in small amounts (M/P ratio unknown for specific formulation; estrogen M/P ratio approximately 0.5, progestin variable). Can reduce milk production and composition. Generally not recommended; use alternative contraception if breastfeeding. Consider benefits versus risks.
PIRMELLA 7/7/7 is contraindicated during pregnancy, thus no dosing adjustments are recommended. If pregnancy is confirmed, the medication should be discontinued immediately.
No dose adjustments as drug is contraindicated in pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) are not relevant due to contraindication.
Take exactly one tablet daily with food to reduce stomach upset.,This supplement contains low iron; you may need additional iron if you have anemia—consult your doctor.,Folic acid dose is very low (7 mcg); ensure you take a separate folic acid supplement (400-800 mcg daily) as advised by your physician.,Do not take with dairy, antacids, or caffeine as they can reduce absorption.,Keep out of reach of children—iron overdose can be fatal.,Store in a cool, dry place away from moisture and heat.
Take one pill daily at the same time. Missing pills increases pregnancy risk.,Use backup contraception (e.g., condoms) for 7 days if you miss a pill, especially in the first week.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first few months.,Do not smoke while taking this medication, especially if over age 35, due to increased risk of blood clots.,This medication does not protect against HIV or other sexually transmitted infections.,Notify your provider if you experience severe headache, chest pain, leg swelling, or vision changes.,Store at room temperature away from moisture and heat.